Cizzle secures VC funding for cancer R&D

23 July 2006

UK-based Cizzle Biotechnology, a spin-out company from the University of York, says it has secured funding from the White Rose Technology Seedcorn Fund which will enable it to continue development of a new diagnostic test for lung cancer. The fund, which was established by the Universities of York, Sheffield and Leeds in the UK, is intended to provide capital for emerging local technologies companies in the biotechnology field.

Cizzle said that it will use the investment to further investigate the role of the Ciz 1 protein in triggering DNA replication and cell growth, as a potential target for the abnormal replication that occurs in cancerous cells. The firm added that it would focus on the development of a diagnostic test and therapy for use in the identification and treatment of small cell lung cancers.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >

Today's issue

Company Spotlight

Ironwood is a US-based biotech advancing a pipeline of medicines in multiple areas of significant unmet need, including irritable bowel syndrome with constipation ((IBS-C)/chronic idiopathic constipation (CIC), vascular and fibrotic diseases, and refractory gastroesophageal reflux disease, among others.